Boundless Bio Inc

NASDAQ:BOLDUnited States

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.

Contact Information

Headquarters

9880 Campus Point Drive, Suite 120SAN DIEGO, CA, United States 92121

Phone

858-766-9912

Fax

302-655-5049

Executives

Chairman of the Board

Jonathan Lim

President, Chief Executive Officer, Director

Zachary Hornby

Principal Financial Officer, Principal Accounting Officer, Treasurer

David Hinkle

Chief Scientific Officer

Christian Hassig

Chief Business Officer

Neil Abdollahian